|

Liver Cancer Clinical Trials in Mesa, AZ

21 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 25 mi
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialPhase 35 mi
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenPhase 35 mi
FOG-001 in Locally Advanced or Metastatic Solid TumorsPhase 1/28 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—8 mi
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid MalignanciesPhase 18 mi
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsPhase 48 mi
A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerPhase 28 mi
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerPhase 28 mi
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)Phase 1/28 mi
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic CholangiocarcinomaPhase 214 mi
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid TumorPhase 114 mi
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform—14 mi
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCCPhase 1/214 mi
Observational Study Protocol: LIVER-R—14 mi
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaPhase 114 mi
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced CancerPhase 114 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPhase 114 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 314 mi
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsPhase 130 mi
DESTINY-PANTUMOUR04—37 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.